| 吴必嘉,龚峻梅,陈娟娟,黄斯勇,高 飞.香菇多糖注射液联合CHOP化疗治疗弥漫性大B细胞淋巴瘤的疗效及对Bcl-6、Ki-67、VEGF、β2-MG表达的影响[J].,2018,(11):2122-2126 |
| 香菇多糖注射液联合CHOP化疗治疗弥漫性大B细胞淋巴瘤的疗效及对Bcl-6、Ki-67、VEGF、β2-MG表达的影响 |
| Curative Efficacy of Lentinan Injection Combined with CHOP Chemotherapy in the Treatment of Diffuse Large B Cell Lymphoma and Its Effects on the Bcl-6, Ki-67, VEGF, β2-MG Expressions |
| 投稿时间：2017-12-26 修订日期：2018-02-07 |
| DOI：10.13241/j.cnki.pmb.2018.11.026 |
| 中文关键词: 香菇多糖注射液 弥漫性大B细胞淋巴瘤 CHOP化疗 疗效 |
| 英文关键词: Lentinan Injection Diffuse large B cell lymphoma CHOP chemotherapy Efficacy |
| 基金项目:国家自然科学基金项目（81300397）；广东省自然科学基金项目（2017A030310649） |
|
| 摘要点击次数: 475 |
| 全文下载次数: 214 |
| 中文摘要: |
| 摘要 目的：探讨香菇多糖注射液联合CHOP化疗治疗弥漫性大B细胞淋巴瘤的疗效及对B细胞淋巴瘤因子-6(Bcl-6)、Ki-67抗原(Ki-67)、内皮细胞生长因子(VEGF)、β2微球蛋白(β2-MG)表达的影响。方法：选取2010年1月~2011年12月我院收治的64例弥漫性大B细胞淋巴瘤患者作为研究对象，按治疗方式进行分组，采用香菇多糖注射液联合CHOP化疗治疗的患者为观察组，单纯采用CHOP化疗治疗的患者为对照组。比较两组患者短期疗效、治疗前后Bcl-6、Ki-67、VEGF、β2-MG的表达情况、不良反应的发生情况及生存情况。结果：治疗后，观察组治疗总有效率显著高于对照组[84.38%(27/32) vs. 53.13(17/32)](P<0.05)；肿瘤组织Bcl-6阳性表达率高于对照组[84.38%(27/32) vs. 62.50%(20/32)](P<0.05)，Ki-67、VEGF、β2-MG阳性表达率均低于对照组[31.25%(10/32) vs. 59.38%(19/32)，28.13%(9/32) vs. 56.25%(18/32)，18.75%(6/32) vs. 40.63%(13/32)](P<0.05)；不良反应总发生率低于对照组[21.88%(7/32) vs. 46.88%(15/32)](P<0.05)；第5年随访时存活率高于对照组[59.38%(19/32) vs. 34.38%(11/32)](P<0.05)。结论：香菇多糖注射液联合CHOP化疗方案治疗弥漫性大B细胞淋巴瘤可有效提高近期疗效、生存率及生存质量，且安全性高，可能与其改善机体肿瘤组织中Bcl-6、Ki-67、VEGF、β2-MG的表达有关。 |
| 英文摘要: |
| ABSTRACT Objective: To study the curative efficacy of lentinan injection combined with CHOP chemotherapy in the treatment of Diffuse large B cell lymphoma and its effects on B-cell lymphoma factor-6(Bcl-6), Ki-67 antigen ( Ki-67), vascular endothelial growth factor (VEGF), β2-microglobulin(β2-MG). Methods: 64 cases of patients with Diffuse large B cell lymphoma who were treated from Jan 2010 to Dec 2011 in our hospital were selected. According to the treatment, the patients treated with lentinan combined with CHOP chemotherapy were taken as the observation group and the patients treated with CHOP chemotherapy alone were considered as the control group. The short-term curative effect, occurrence of adverse reactions, survival rate, positive expression of Bcl-6, Ki-67, VEGF and β2-MG before and after treatment were compared between the two groups. Results: After treatment, the total effective rate of observation group was significantly higher than that of the control group[84.38%(27/32) vs. 53.13(17/32)](P<0.05); the positive rate of Bcl-6 was higher than that of the control group[84.38%(27/32) vs. 62.50%(20/32)](P<0.05), the positive rates of Ki-67, VEGF and β2-MG were lower than those of the control group[31.25%(10/32) vs. 59.38%(19/32), 28.13%(9/32) vs. 56.25%(18/32), 18.75%(6/32) vs. 40.63%(13/32)](P<0.05); the total incidence of adverse reactions was lower than that of the control group[21.88%(7/32) vs. 46.88%(15/32)](P<0.05); the survival rate at the fifth year follow-up was higher than that of the control group[59.38%(19/32)vs 34.38%(11/32)](P<0.05). Conclusion: Lentinan Injection combined with CHOP chemotherapy can effectively improve the short-term efficacy, survival rate and quality of life with high safety in the treatment of diffuse large B cell lymphoma. It may be related to improve the expression of Bcl-6, Ki-67, VEGF and beta 2-MG in tumor tissue. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
